Vaxart, Inc. (NASDAQ:VXRT), a biotechnology company specializing in the development of oral recombinant vaccines with a market capitalization of approximately $159 million, announced on Monday an ...

Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells—the body's frontline ...

On Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Ratner, who heads the pediatric infectious disease unit at NYU Langone’s Hassenfeld Children’s Hospital, tracks the history ...